Infection as a cause of irritable bowel syndrome

Hospital Medicine

Volumn 64, Issue 5, 2003, Pages 270-274

  Spiller, R C ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILE SALT; LOPERAMIDE; SEROTONIN ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; BILE ACID;

ABDOMINAL DISTENSION; BACTERIAL INFECTION; CLINICAL FEATURE; CONFERENCE PAPER; DIARRHEA; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INCIDENCE; IRRITABLE COLON; MALABSORPTION; MUCOSA; PATHOGENESIS; PROGNOSIS; PROTECTION; PSYCHOLOGICAL ASPECT; RISK FACTOR; SIDE EFFECT; VOMITING; ANAMNESIS; INFECTION; INTESTINE MUCOSA; MENTAL DISEASE; METABOLISM; MICROBIOLOGY; REVIEW;

BILE ACIDS AND SALTS; COLONIC DISEASES, FUNCTIONAL; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFECTION; INTESTINAL MUCOSA; MALABSORPTION SYNDROMES; MEDICAL HISTORY TAKING; MENTAL DISORDERS; PROGNOSIS; RISK FACTORS;

EID: 0037867839     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2003.64.5.1758     Document Type: Conference Paper

References (28)

1. Bearcroft CP, Perrett D, Farthing MJ (1998) Postprandial plasma 5-hydroxytryptamine in diarrhoea-predominant irritable bowel syndrome: a pilot study. Gut 42: 42-6
2. 3 receptor antagonist. Aliment Pharmacol Ther 13: 1149-59
3. Chaudhary NA, Truelove SC (1962) The irritable colon syndrome. Q J Med 123: 307-22
4. Drossman DA, McKee DC, Sandler RS et al (1988) Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 95: 701-8
5. Drossman DA, Thompson WG, Talley NJ, Funch-Jensen P, Janssens J, Whitehead WE (1990) Identification of subgroups of functional gastrointestinal disorders. Gastroent Int 3: 159-72
6. Dunlop SP, Jenkins D, Spiller RC (2001) Distinctive clinical and histological features of post-infectious IBS. Gut 48: A44
7. Gwee KA, Graham JC, McKendrick MW et al (1996) Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 347: 150-3
8. Gwee KA, Leong YL, Graham C et al (1999) The role of psychological and biological factors in postinfective gut dysfunction. Gut 44: 400-6
9. Harvey RF, Mauad EC, Brown AM (1987) Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet i: 963-5
10. 3 receptor antagonist, delays colonie transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 14: 775-82
11. Jones J, Boorman J, Cann P et al (2000) British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 47(suppl 2): II1-II19
12. Koloski NA, Talley NJ, Boyce PM (2001) Predictors of healthcare-seeking for irritable bowel syndrome and non-ulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol 96: 1340-9
13. Lavo B, Stenstam M, Nielsen A-L (1987) Loperamide in treatment of irritable bowel syndrome - a double-blind, placebo-controlled study. Scand J Gastroenterol 22(suppl): 77-80
14. Longstreth GF, Hawkey CJ, Ham J et al (2000) Demographic and clinical characteristics of patients with irritable bowel syndrome from three practice settings. Gastroenterology 118: A146
15. Myren J, Lovland B, Larssen S-E, Larsen S (1984) A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 19: 835-43
16. Neal KR, Hebden J, Spiller R (1997) Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 314: 779-82
17. Neal KR, Barker L, Spiller RC (2002) Prognosis in post-infective irritable bowel syndrome: a six-year follow-up study. Gut 51: 410-13
18. Niaz SK, Sandrasegaran K, Renny FH, Jones BJ (1997) Postinfective diarrhoea and bile acid malabsorption. J Roy Coll Phys Lond 31: 53-6
19. Parker TJ, Naylor SJ, Riordan AM, Hunter JO (1995) Management of patients with food intolerance in irritable bowel syndrome: the development and use of an exclusion diet. J Hum Nutr Diet 8: 159-66
20. Parry SD, Barton R, Welfare MR (2001) Prevalence of pre-existing functional gastrointestinal disorders in infectious diarrhoea subjects compared to a matched community control group. Gastroenterology 120: A-633
21. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL (1998) Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 43: 400-11
22. Ragnarsson G, Bodemar G (1999) Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples. Scand J Gastroenterol 34: 993-1000
23. Rodriguez LA, Ruigomez A (1999) Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 318: 565-6
24. Spiller RC, Jenkins D, Thornley JP et al (2000) Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47: 804-11
25. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA (1999) Functional bowel disorders and functional abdominal pain. Gut 45(suppl 2): II43-II47
26. Thompson WG, Heaton KW, Smyth GT, Smyth C (2000) Irritable bowel syndrome in general practice: prevalence, characteristics and referral. Gut 46: 78-82
27. Thornley JP, Jenkins D, Neal K, Wright T, Brough J, Spiller RC (2001) Relationship of Campylobacter toxigenicity in vitro to the development of post-infectious irritable bowel syndrome. J Infect Dis 184: 606-9
28. Vanner SJ, Depew WT, Paterson WG et al (1999) Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 94: 2912-17